PSA Nadir Is a Significant Predictor of Treatment Failure after High-Intensity Focussed Ultrasound (HIFU) Treatment of Localised Prostate Cancer
Authors:
- Roman GanzerRGRoman Ganzer
- Sebastian RogenhoferSRSebastian Rogenhofer
- Bernhard WalterBWBernhard Walter
- Jens-Claudio LunzJLJens-Claudio Lunz
- Martin SchostakMSMartin Schostak
- Wolf F. WielandWWWolf F. Wieland
- Andreas BlanaABAndreas Blana
- 1 March 2008
- journal article
- research article
- Published by Elsevier in European Urology
- Vol. 53 (3) , 547-553
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Prostate‐specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and deathCancer, 2006
- Visually directed high‐intensity focused ultrasound for organ‐confined prostate cancer: a proposed standard for the conduct of therapyBJU International, 2006
- Current Status of HIFU and Cryotherapy in Prostate Cancer – A ReviewEuropean Urology, 2006
- Evaluation of Color Doppler in Guiding Prostate Biopsy after HIFU AblationEuropean Urology, 2006
- Treatment of localized prostate cancer using high‐intensity focused ultrasoundBJU International, 2005
- Technology Insight: high-intensity focused ultrasound for urologic cancersNature Reviews Endocrinology, 2005
- Early prostate‐specific antigen (PSA) kinetics following prostate carcinoma radiotherapyCancer, 2004
- Management of prostate-specific antigen relapse in prostate cancer: A European consensusInternational Journal Of Clinical Practice, 2004
- High-Intensity Focused Ultrasound and Localized Prostate Cancer: Efficacy Results from the European Multicentric StudyJournal of Endourology, 2003
- DEFINING PROSTATE SPECIFIC ANTIGEN PROGRESSION AFTER RADICAL PROSTATECTOMY: WHAT IS THE MOST APPROPRIATE CUT POINT?Journal of Urology, 2001